BioMérieux BIOFIRE Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Becomes First COVID-19 Diagnostic Test to Obtain De Novo FDA Authorization
|
By HospiMedica International staff writers Posted on 19 Mar 2021 |

Image: BIOFIRE RP2.1 Panel (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has received US Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE RP2.1 Panel, making it the first SARS-CoV-2 diagnostic test of any kind to be granted De Novo status by US FDA.
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays
Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more
Causal AI Tool Withholds Ovarian Cancer Treatment Recommendations When Evidence Insufficient
Ovarian cancer treatment often requires individualized decisions, particularly when available patient data do not clearly favor one therapeutic approach. However, artificial intelligence (AI) systems may... Read moreCritical Care
view channel
Wearable Patch Enables Continuous Troponin Monitoring for Postoperative Cardiac Injury
Myocardial injury after noncardiac surgery (MINS) is heart muscle damage that occurs following procedures not involving the heart. Detecting MINS is challenging because most cases are asymptomatic and... Read more
Wearable Heart Mapping May Help Identify Cardiovascular Hospitalization Risk
Cardiac scar tissue can develop when heart muscle cells die and fail to regenerate, often due to vascular blockages or age-related changes, even in individuals without a history of heart attack.... Read moreSurgical Techniques
view channel
Modular Robotic Surgery System Cleared for General Surgery Procedures
Upper and lower abdominal procedures, including cholecystectomy, hernia repair, small-bowel resection, and gastric bypass, account for approximately 3.5 million operations annually in the U.... Read more
FDA Authorizes Robotic System for En Bloc Bladder Resection
Bladder cancer frequently recurs, making accurate staging essential for treatment planning. Conventional transurethral resection can fragment tumors, complicating margin assessment and detrusor muscle... Read more
Fluorescence Imaging Reveals Nerves Under Normal Operating-Room Lighting
Preventing unintended nerve injury remains a major concern during surgery, particularly in complex anatomical regions where nerves can be difficult to distinguish from surrounding tissue.... Read more
Programmable Microwave Ablation System Gains CE Mark for Minimally Invasive Tissue Ablation
Hospitals continue to seek minimally invasive approaches that simplify procedural planning and provide controlled energy delivery for tissue ablation. Thermal ablation systems are used across multiple... Read morePatient Care
view channelVirtual Reality Program May Reduce Anxiety Before Pediatric Surgery
Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more
Video-Based Support Helps Older Adults Clarify Kidney Disease Treatment Preferences
Advanced chronic kidney disease (CKD) involves progressive loss of kidney function that can lead to kidney failure and difficult treatment decisions. For older adults, these decisions may include choosing... Read moreMedical Imaging
view channel
AI Uses Routine MRI to Predict Deep Brain Stimulation Response in Dystonia
Dystonia is a debilitating neurological movement disorder characterized by involuntary muscle contractions that cause abnormal movements and postures. Deep brain stimulation (DBS) is one of the few treatments... Read more
AI Combines Brain Imaging Features to Identify Cognitive Impairment in CKD
Chronic kidney disease (CKD) can affect multiple organs, including the brain, with cognitive impairment emerging as a common complication. Changes in executive function, attention, and memory can reduce... Read moreAI Software Gains FDA Clearance for Brain Aneurysm Detection and Follow-Up
Unruptured intracranial aneurysms are often asymptomatic and can be difficult to detect on head computed tomography angiography, especially in busy acute-care workflows. Missed or delayed identification... Read more
Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis
Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read moreHealth IT
view channel
Telemonitoring Program Improves Quality of Life After Heart Failure Discharge
Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more
Clinical Decision Support Tool Automates CKD Risk Assessment in Primary Care
Chronic kidney disease (CKD) requires timely diagnosis, risk assessment, and coordinated treatment in primary care. Delayed recognition can affect decisions about testing, blood pressure control, cardiovascular... Read morePoint of Care
view channel
Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier
Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more
New Breath Condensate Testing Approach Enhances Reliability for COPD Monitoring
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that can increasingly impair breathing over time. Diagnosis and monitoring may be burdensome because patients often require... Read more
Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes
Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read moreBusiness
view channel
Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings
Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more








